{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 24 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '4.', 'TREATMENTS', '4.1', 'INVESTIGATIONAL TREATMENTS', '4.1.1', 'Identity of the investigational medicinal products', 'No study medication is included in this trial, this trial is a comparison of pulmonary', 'rehabilitation versus standard care in patients with IPF already taking a stable dose of', 'nintedanib. The active treatment arm will consist of a standard pulmonary rehabilitation', 'regimen two or three times weekly for 12 weeks. Patients assigned to PR will be referred to a', \"facility convenient for the patient. The pulmonary rehabilitation should follow the facility's\", 'standard regimen as long as the regimen meets basic standards (to be provided in the ISF).', 'No study specific data collection is required by the PR facility, however standard treatment', 'reports must be available to the investigator to document the attendance and progress of PR.', '4.1.2', 'Selection of doses in the trial', 'Patients are required to be using the FDA (Food and Drug Administration) approved dose of', 'nintedanib 150 mg BID for up to 30 months to qualify for the trial and to continue on', 'nintedanib for the duration of the trial. Patients who have recently started nintedanib 150 mg', 'BID and have started by the day of randomization must be on nintedanib 150 mg BID a', 'minimum of 10 days by the first day of pulmonary rehabilitation. Temporary dose adjustment', 'for the management of adverse events is allowed during the conduct of the study.', '4.1.3', 'Method of assigning patients to treatment groups', 'During visit 2 eligible patients will be randomised to either continue on nintedanib treatment', 'alone or continue on nintedanib with a pulmonary rehabilitation program added in a 1:1 ratio', 'according to a randomization plan. The assignment will occur via Interactive Response', 'Technology (IRT).', '4.1.4', 'Drug assignment and administration of doses for each patient', 'Subjects are required to be treated on a stable (up to 30 months) dose of nintedanib 150 mg', 'BID, administered per prescribing instructions (R18-1289), to enter the trial and to continue', 'on this dose throughout the trial. Patients who have recently started nintedanib 150 mg BID', 'and have started by the day of randomization must be on nintedanib 150 mg BID a minimum', 'of 10 days by the first day of pulmonary rehabilitation. Patients that have had an interruption', 'in nintedanib treatment or a temporary dose reduction can be entered into the trial when they', 'have returned to a dose of 150mg BID and their condition is determined to be stable by the', 'investigator and temporary dose reductions to treat adverse events is permitted during the', 'trial.', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 25 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '4.1.5', 'Blinding and procedures for unblinding', '4.1.5.1', 'Blinding', 'Qualified subjects will be randomized at Visit 2 to either continue with their usual treatment', 'or to add a pulmonary rehabilitation program to their usual treatment. In this open-label trial,', 'treatment allocation will not be concealed throughout the trial. The CRF will contain', 'information on randomised treatment. As patients are randomized to either no pulmonary', 'rehabilitation or pulmonary rehabilitation, it is not possible to blind the treatments in this', 'trial.', '4.1.5.2', 'Unblinding and breaking the code', 'Not applicable, this trial is not blinded.', '4.1.6', 'Packaging, labelling, and re-supply', 'Not applicable, no study medication is provided in this trial.', '4.2', 'OTHER TREATMENTS, EMERGENCY PROCEDURES,', 'RESTRICTIONS', '4.2.1', 'Other treatments and emergency procedures', '4.2.1.1', 'Management of adverse events related to nintedanib', 'Adverse events related to nintedanib should be managed according to the current package', 'insert (R18-1289) in conjunction with the prescribing physician.', '4.2.1.2 Management of other adverse events', 'Adverse events related to the study procedures such as pulmonary rehabilitation, 6MWT', 'as well as unrelated adverse', 'events, will be managed as clinically indicated. If a patient experiences an adverse event', 'which impacts their ability to continue with pulmonary rehabilitation (if assigned) or ability', 'to continue with the exercise testing, the clinical monitor should be consulted regarding', 'continued participation in the trial prior to discontinuation.', '4.2.2', 'Restrictions', '4.2.2.1', 'Restrictions on concomitant treatment', 'The following drugs must not be taken within 8 weeks of visit 1:', 'Pirfenidone', 'Any other experimental IPF therapy.', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}